Hims & Hers Health (NYSE: HIMS) Shares Surge 10-13% Intraday Thursday July 23 Following the FDA PCAC Advisory Panel Vote in Favor of Adding BPC-157 and KPV to the 503A Compounding Pathway; Chief Medical Officer Dr. Anant Vinjamoori's Testimony Included the Anecdote That a Colleague Recently Sent Him a Photograph of a Bodega in Queens Selling Peptides, Arguing That a No Vote Would Push the Trade Deeper Into an Unregulated Gray Market With 'No Production or Sourcing Standards, No Physician, No Monitoring, and No Record'
Hims & Hers Health (NYSE: HIMS) shares surged 10-13% intraday on Thursday July 23, 2026 following the FDA Pharmacy Compounding Advisory Committee (PCAC) 8-6 votes in favor of adding BPC-157 and KPV to the Section 503A Bulks List. The stock reaction reflected investor recognition that Hims & Hers is one of the largest telehealth commercial channels positioned to sell legally compounded peptides through licensed 503A pharmacies if the FDA follows the advisory recommendation and completes rulemaking. Hims Chief Medical Officer Dr. Anant Vinjamoori's public-comment testimony was reportedly influential in the panel outcome. Vinjamoori shared the anecdote that a colleague had recently sent him a photograph of a bodega in Queens selling peptides, then argued: 'A no vote would not end those distribution channels or use. It would instead move it deeper into a market with no production or sourcing standards, no physician, no monitoring, and no record.' Vinjamoori also acknowledged the 'relatively sparse clinical evidence for these peptides' before making the harm-reduction argument. Hims stands to benefit commercially: the company has built peptide capabilities including a California manufacturing facility acquired in 2025.